Cambrex adds new development and analytical equipment in Italy

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/suprunvitaly)
(Image: Getty/suprunvitaly)

Related tags: Active ingredient

Cambrex Corporation has announced a new investment in its research and development (R&D) and manufacturing capabilities at its site in Paullo, Milan, Italy.

According to the company, it has installed development and analytical equipment to support the development of highly potent APIs (HPAPIs), including a new 2,800-liter hydrogenator and 1,500mm diameter centrifuge.

Equipment installation and validation with be concluded by the end of 2017.

The small molecule and generic Active Pharmaceutical Ingredients (APIs) manufacturer opened the pilot plant in October 2016 at which time it said further upgrades would follow in order to support the production of Class 3/4 high potency products.

The cGMP plant can produce batch sizes from 1kg to 15kg.

Cambrex also invested $24m​ in a new Charles City, Iowa plant earlier this year. The facility is expected to be open in 2019.

The company’s High Point, NC-based facility was also expanded​ to include a new $3.2m, 11,000 square foot analytical laboratory in August. 

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us


View more